Key result
Platelets from diabetic subjects showed diminished sensitivity to the antiaggregatory effects of prostacyclin in vitro, which may contribute to increased vascular disease in this population.
Why the study?
Does prostacyclin have diminished antiaggregatory effects on platelets from diabetic subjects in vitro?
Observational
Does prostacyclin have diminished antiaggregatory effects on platelets from diabetic subjects in vitro?
Diminished sensitivity of platelets to prostacyclin in diabetic patients may help explain their increased risk of vascular disease.
No takes yet. Share an insight, caveat, or question.
May underlie thrombotic risk in diabetes; hypothesis-generating and requires in vivo confirmation before clinical consideration.
Betteridge et al. (1982) conducted an observational in Diabetes. Prostacyclin (in vitro) was evaluated on Sensitivity of platelets to the antiaggregatory effects of prostacyclin in vitro. Platelets from diabetic subjects showed diminished sensitivity to the antiaggregatory effects of prostacyclin in vitro, which may contribute to increased vascular disease in this population.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: